Skip to main content
SpringerLink
Log in

Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring

  • Original Research
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib and the cytotoxic agent docetaxel are both used for the second-line treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of gefitinib in combination with docetaxel within this disease setting, and to evaluate the predictive value of assessing pre-treatment levels of soluble serum EGFR and HER2. In this open-label, non-comparative, multicenter, phase II trial, patients with non-resectable advanced or metastatic NSCLC were treated with oral gefitinib (250 mg/day) in combination with docetaxel (75 mg/m2 IV every 3 weeks). Forty-eight patients were enrolled: 30 had progressed during or after platinum-based chemotherapy (Group A) and 18 were unsuitable for platinum-based chemotherapy (Group B). Anti-tumor activity was seen with objective response rates of 23.3% (Group A) and 11.8% (Group B). The most frequent adverse events considered to be gefitinib-related were diarrhea (57.4%) and skin-related events (dry-skin: 31.9%; rash: 29.8%; pruritus: 12.8%), and those considered to be docetaxel-related were alopecia (21.3%), nausea (19.1%), and diarrhea (17.0%). The addition of gefitinib did not seem to affect the hematological toxicity seen with docetaxel. Serum biomarker investigations revealed that patients who responded had lower serum EGFR levels than non-responders, although this association was not significant (p=0.07). In conclusion, the combination of gefitinib with docetaxel was feasible, generally well tolerated, and has activity for the treatment of advanced NSCLC. Soluble serum EGFR (and HER2 levels) did not appear to be predictive for response. Although this study confirms that the combination of gefinitib and docetaxel appears promisingly effective and tolerable, it should not be recommended as a standard option for second-line therapy in non-small cell lung cancer until results from phase III trials showing a significant superiority over docetaxel alone are available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Addition of platinum compounds to a new agent in patients with advanced non-small cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15:1782–1789

    Article  PubMed  CAS  Google Scholar 

  2. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

    PubMed  CAS  Google Scholar 

  3. Fossella FV, Devore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362

    PubMed  CAS  Google Scholar 

  4. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (IRESSA), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885–4892

    PubMed  CAS  Google Scholar 

  5. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237–2246

    Article  PubMed  CAS  Google Scholar 

  6. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290:2149–2158

    Article  PubMed  CAS  Google Scholar 

  7. World Medical Association (1997) World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926

    Article  Google Scholar 

  8. National Cancer Institute (1999) Cancer Therapy Evaluation Program. Common Toxicity Criteria manual. Common Toxicity Criteria, Version 2.0. http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf

  9. Kim KS, Jeong JY, Kim YC et al (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11:2244–2251

    Article  PubMed  CAS  Google Scholar 

  10. Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22:1103–1109

    Article  PubMed  CAS  Google Scholar 

  11. Park J, Park BB, Kim JY et al (2004) Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10:4383–4388

    Article  PubMed  CAS  Google Scholar 

  12. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib (IRESSA) plus best supportive care in pretreated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (ISEL). Lancet 366:1527–1537

    Article  PubMed  CAS  Google Scholar 

  13. Cufer T, Vrdoljak E, on behalf of the SIGN Study Group (2005) Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 23:629s, abstract 7035

    Google Scholar 

  14. Robinet G, Falchero L, Perol M, Thomas P, Monnet I, Grivaux M, Crequit J, Letreut J, Paillotin D, Chouaid C (2005) A randomized Phase II trial of docetaxel alone and in combination with gefitinib as second-line therapy for patients with non-small-cell lung cancer. Proceedings from the 11th World Conference on Lung Cancer, Barcelona, Spain: abstract #O-091

  15. Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A (2005) A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 6:343–349

    Article  PubMed  CAS  Google Scholar 

  16. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  17. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655

    Article  PubMed  CAS  Google Scholar 

  18. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  19. Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081–8092

    Article  PubMed  CAS  Google Scholar 

  20. Hirsch FR, Varella-Garcia M, Bunn PA et al (2005) Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in patients with advanced non-small cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial). AACR-NCI-EORTC, Miami Beach, Florida, USA, November 14–November 18, abstract 268

  21. Bailey LR, Kris M, Wolf M et al (2003) Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (IRESSA, ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44 (2nd edition):1362, Abs LB-170

  22. Tsao M-S, Sakurada A, Cutz J-C et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank AstraZeneca for critical review of the manuscript, Emma Boning from Complete Medical Communications, who provided medical writing support on behalf of AstraZeneca, and the AVEC association for support in biological monitoring of the study.

Author information

Authors and Affiliations

  1. Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie (Paris 6), Service d’Oncologie Médicale, 47 Boulevard de l’Hôpital, 75013, Paris, France

    M. Gatineau, R. Mouawad, D. Khayat & O. Rixe

  2. Centre Oscar Lambret, Lille, France

    E. Dansin

  3. Institut Bergonié, Bordeaux, France

    F. Chomy

  4. Hôpital Bretonneau, Tours, France

    E. Lemarie

  5. Clinique Cap D’Or, La Seyne/Mer, France

    P. Nouyrigat

  6. Hôpital G Pompidou, Paris, France

    S. Oudard

  7. AstraZeneca, Rueil, France

    A. Tisseron Carrasco

Authors
  1. M. Gatineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Dansin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Chomy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Lemarie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Nouyrigat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Oudard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Mouawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Tisseron Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Khayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O. Rixe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Rixe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gatineau, M., Dansin, E., Chomy, F. et al. Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. Targ Oncol 1, 114–122 (2006). https://doi.org/10.1007/s11523-006-0023-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-006-0023-4

Keywords

Search

Navigation